424
Views
7
CrossRef citations to date
0
Altmetric
Special Report

Novel anti-obesity drugs and plasma lipids

, , , , , & show all
Pages 179-187 | Published online: 18 Jan 2017
 

Abstract

Obesity is a health problem of global, epidemic proportions and a major risk factor for chronic diseases resulting in accelerated morbidity and mortality. Dyslipidemia with a predominance of small dense LDL, impaired functionality of HDL particles, and increased serum levels of remnant particles due to impaired clearance of triglyceriderich lipoproteins significantly heightens cardiovascular events in obese subjects. Pharmacotherapy in combination with lifestyle modification is the primary approach to reduce obesity-related cardiovascular risk. Although there are several potential anti-obesity drugs, orlistat is the only agent that remains available in the market. Lorcaserin and Qsymia®, approved by the US FDA last year, and contrave with potential approval in 2014, are new anti-obesity drugs with promising therapeutic effects. Although these drugs can be associated with adverse side effects, these agents have favorable effects on lipid profiles. However, the need for safer anti-obesity agents is clear.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.